Appili Therapeutics Inc Class A (TSE:APLI)
TSX:APLI
Top Page
Appili Therapeutics Inc Class A
(TSX:APLI)
Select Model
Select Model
Rating:42Neutral
Price Target:
C$0.01
▼(-30.00% Downside)
Action:ReiteratedDate:02/18/26
The score is held down primarily by weak financial performance, especially negative equity, substantial losses, and reliance on external funding. Technicals are also mildly bearish (negative MACD and below key moving averages), while valuation signals are not supportive due to negative earnings and no dividend yield data.
Positive Factors
Focused infectious-disease pipeline
Appili’s concentrated clinical-stage focus on antibacterial, antiviral and antifungal candidates creates a durable strategic niche. A clear pipeline (ATI-2307, ATI-1501) supports milestone-driven value creation, enhances partner appeal and aligns with persistent public-health demand over months.
Negative Factors
Negative shareholders' equity and thin balance sheet
The balance sheet shows negative shareholders’ equity and sizable debt (~$12.5M) against very small total assets, creating a structurally thin capital base. This materially limits financial flexibility, raises refinancing risk and constrains the company’s ability to fund clinical development without external financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused infectious-disease pipeline
Appili’s concentrated clinical-stage focus on antibacterial, antiviral and antifungal candidates creates a durable strategic niche. A clear pipeline (ATI-2307, ATI-1501) supports milestone-driven value creation, enhances partner appeal and aligns with persistent public-health demand over months.
Read all positive factors
Appili Therapeutics Inc Class A (APLI) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$2.57M
Dividend YieldN/A
Average Volume (3M)72.91K
Price to Earnings (P/E)―
Beta (1Y)0.95
Revenue Growth-58.01%
EPS Growth29.73%
CountryCA
Employees8
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding128,366,120
10 Day Avg. Volume40,186
30 Day Avg. Volume72,908
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-0.39
Price to Sales (P/S)5.13
P/FCF Ratio-1.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Appili Therapeutics Inc Class A Business Overview & Revenue Model
Company Description
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes Favipiravir for pandemic influenza and ...
How the Company Makes Money
Appili Therapeutics’ revenue model is primarily typical of a pre-commercial, clinical-stage biotech: it generally does not generate meaningful recurring product sales and instead funds operations through external financing and non-dilutive support...
Appili Therapeutics Inc Class A Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
20
Very Negative
| Breakdown | TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2020 | Jun 2019 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 206.31K | 100.44K | 334.18K | 1.39M | 0.00 | 199.11K |
| Gross Profit | 199.58K | 100.44K | 327.91K | 1.39M | -14.84K | 199.11K |
| EBITDA | -1.59M | 360.57K | -8.10M | -23.51M | -14.87M | -5.63M |
| Net Income | -2.96M | -2.62M | -9.24M | -25.12M | -14.33M | -5.42M |
Balance Sheet | ||||||
| Total Assets | 547.91K | 3.03M | 3.13M | 8.28M | 18.32M | 11.17M |
| Cash, Cash Equivalents and Short-Term Investments | 212.75K | 1.23M | 2.47M | 6.66M | 16.12M | 10.54M |
| Total Debt | 12.46M | 12.29M | 7.67M | 4.98M | 1.03M | 1.00M |
| Total Liabilities | 16.93M | 16.43M | 10.53M | 11.55M | 5.56M | 2.33M |
| Stockholders Equity | -16.38M | -13.40M | -7.40M | -3.27M | 12.75M | 8.85M |
Cash Flow | ||||||
| Free Cash Flow | -24.57K | 866.46K | -10.10M | -19.08M | -11.46M | -4.26M |
| Operating Cash Flow | -24.57K | 868.82K | -10.10M | -19.08M | -11.45M | -4.26M |
| Investing Cash Flow | 0.00 | -2.36K | -3.17K | 5.06M | -4.99M | -1.14K |
| Financing Cash Flow | -18.17K | 193.68K | 5.91M | 9.56M | 17.02M | 9.36M |
Appili Therapeutics Inc Class A Technical Analysis
Neutral
0.02
Price Trends
0.02
Positive
0.02
Negative
0.02
Negative
Market Momentum
>-0.01
Negative
54.25
Neutral
33.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:APLI, the sentiment is Neutral. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.02, and below the 200-day MA of 0.02, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 54.25 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:APLI.
Appili Therapeutics Inc Class A Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | C$589.63K | -6.34 | -10.30% | ― | ― | 46.32% | |
42 Neutral | C$2.57M | -0.84 | 19.73% | ― | -58.01% | 29.73% | |
42 Neutral | C$835.47K | -0.20 | -111.11% | ― | ― | -1939.32% | |
42 Neutral | C$44.21M | -17.16 | ― | ― | -41.70% | -35.42% | |
41 Neutral | C$5.46M | -3.10 | ― | ― | ― | ― | |
| ― | C$1.89M | -1.60 | ― | ― | ― | 25.09% |
* Healthcare Sector Average
TSE:APLI
Appili Therapeutics Inc Class A
0.02
>-0.01
-33.33%
TSE:XRTX
XORTX Therapeutics Inc
0.60
-0.72
-54.55%
TSE:KNE
Kane Biotech
0.03
-0.07
-70.00%
TSE:MIR
Medmira
0.06
-0.02
-25.88%
TSE:VXL
Vaxil Bio
0.15
-0.10
-40.80%
TSE:BIOV
BioVaxys Technology
0.07
-0.39
-85.56%
Appili Therapeutics Inc Class A Corporate Events
Business Operations and StrategyPrivate Placements and FinancingProduct-Related Announcements
Appili Therapeutics Targets New Funding and Partnerships at World Vaccine Congress Washington
Positive
Mar 30, 2026
Appili Therapeutics will exhibit at the World Vaccine Congress Washington 2026, where its CEO and chief development officer plan to highlight recent collaborations and funding milestones while seeking additional non-dilutive financing. The company...
Business Operations and StrategyPrivate Placements and Financing
Appili Therapeutics Raises C$100,000 in Second Tranche of Private Placement
Positive
Feb 18, 2026
Appili Therapeutics Inc., a Halifax-based biopharmaceutical company specializing in anti-infective therapies and medical countermeasures, has built a diversified portfolio that includes an FDA-approved metronidazole suspension for resistant infect...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Appili Deepens Non-Dilutive Funding Base as Infectious Disease Pipeline Advances
Positive
Feb 12, 2026
Appili reported third-quarter fiscal 2026 results that underscore its strategy of leveraging non-dilutive government funding and partnerships to advance its infectious disease and biodefense pipeline. The company has secured more than US$75 millio...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.